Blujepa is the first in a new class of oral antibiotics in 30 years. It is expected to launch in the second half of 2025 in the United States.

Over the last 25 years, (ED) medications such as Viagra and others have become common and normal pieces of bedroom tool kit.

For details about CYP3A4 inhibitors, see the “Ubrelvy in depth ... Keep in mind that nausea can also be a common side effect of Ubrelvy itself. In addition, both ondansetron and promethazine ...

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with ...

The most common reasons for discontinuing drug were ... be reduced to 25 mg once daily in patients receiving weak CYP3A4 inhibitors (such as erythromycin, saquinavir, verapamil, and fluconazole).

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close ...

Harmony Biosciences Holdings, Inc. , today announced the appointment of Adam Zaeske as Executive Vice President and Chief Commercial Officer (CCO), effective March 31, 2025. The company's current CCO, ...

In a live event, Ganesh V. Raj, MD, PhD, discussed the drug-drug interactions and outcomes by disease volumes across ARPI trials in mHSPC.

The following is a summary of “Naldemedine Use and Healthcare Resource Utilization in Patients treated with Opioid Analgesics for Chronic Non-Cancer Pain: Results of a Real-world Study in the USA,” ...

from the ongoing healthy volunteer study demonstrate that TERN-701 is not a clinically relevant inhibitor of CYP3A4 or OATP1B1/3 Results support dosing of TERN-701 with common concomitant ...